U.S. Cell Reprogramming Market Size & Outlook, 2023-2030
U.S. cell reprogramming market, 2018-2030 (US$M)
Related Markets
U.S. cell reprogramming market highlights
- The U.S. cell reprogramming market generated a revenue of USD 132.8 million in 2023 and is expected to reach USD 227.9 million by 2030.
- The U.S. market is expected to grow at a CAGR of 8% from 2024 to 2030.
- In terms of segment, mrna reprogramming was the largest revenue generating technology in 2023.
- MRNA Reprogramming is the most lucrative technology segment registering the fastest growth during the forecast period.
Cell reprogramming market data book summary
| Market revenue in 2023 | USD 132.8 million |
| Market revenue in 2030 | USD 227.9 million |
| Growth rate | 8% (CAGR from 2023 to 2030) |
| Largest segment | Mrna reprogramming |
| Fastest growing segment | MRNA Reprogramming |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Sendai Virus-based Reprogramming, MRNA Reprogramming, Episomal Reprogramming |
| Key market players worldwide | Thermo Fisher Scientific Inc, Merck KGaA, Bio-Techne Corp, ReproCELL, Lonza Group Ltd, FUJIFILM Holdings Corp, Astellas Pharma Inc, Allele Biotech, Alstem, STEMCELL Technologies |
Other key industry trends
- In terms of revenue, U.S. accounted for 35.4% of the global cell reprogramming market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. cell reprogramming market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 24.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell Reprogramming Market Scope
Cell Reprogramming Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. cell reprogramming market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell reprogramming market will help companies and investors design strategic landscapes.
Mrna reprogramming was the largest segment with a revenue share of 33.58% in 2023. Horizon Databook has segmented the U.S. cell reprogramming market based on sendai virus-based reprogramming, mrna reprogramming, episomal reprogramming covering the revenue growth of each sub-segment from 2018 to 2030.
Many market players in the U.S. are continuously working on cell reprogramming for research. The presence of innovators and major market players has resulted in higher product penetration in the country.
Furthermore, a structured environment for cell reprogramming and the local presence of key companies, such as Century Therapeutics, FUJIFILM Cellular Dynamics, Pluristyx, and Bio-Techne Corporation, are boosting market growth. For instance, in July 2023, Stem Genomics SAS and Pluristyx, Inc. announced an equity investment and partnership in Stem Genomics.
This collaboration aims to provide a streamlined approach, enabling customers to assess the genomic strength of Pluripotent Stem Cell (PSC) lines of Pluristyx by leveraging iCS-digital PSC assay of Stem Genomics.
Reasons to subscribe to U.S. cell reprogramming market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. cell reprogramming market databook
-
Our clientele includes a mix of cell reprogramming market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. cell reprogramming market , including forecasts for subscribers. This country databook contains high-level insights into U.S. cell reprogramming market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. cell reprogramming market size, by technology, 2018-2030 (US$M)
U.S. Cell Reprogramming Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
